Literature DB >> 8354131

An improved assay for the detection of Toxoplasma gondii antibodies in human serum by flow cytometry.

G Cozon1, C Roure, G Lizard, T Greenland, D Larget-Piet, F Gandilhon, F Peyron.   

Abstract

The diagnosis of toxoplasmosis relies primarily on the demonstration of specific antibodies to Toxoplasma gondii. We describe a flow cytometry method for the determination of antibodies to whole fixed tachyzoites by indirect immunofluorescence. Fixed tachyzoites in suspension have characteristic light scattering properties. The amount of IgM, IgG, and IgA antibodies from patients' sera bound to the tachyzoites can be estimated from the mean fluorescence intensities observed using class-specific conjugates for different Ig heavy chains. Appropriate serum dilutions for the estimation of specific IgG titres and for the discrimination between sera positive and negative for IgA and IgM antibodies were established using 40 random sera from pregnant women. The method proved to be quantitative and highly sensitive as compared with currently used assays. Coefficients of variation between series ranged from 6.4% to 12.2% and could be controlled by the inclusion of positive and negative standard sera in the test series. The method might represent a major improvement in cost effectiveness as compared with routine immunofluorescence assay by fluorescent microscopy when the volume of testing is sufficient. It can be fully automated, and its large scale application is currently under investigation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8354131     DOI: 10.1002/cyto.990140518

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  9 in total

Review 1.  Uses of flow cytometry in virology.

Authors:  J J McSharry
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

2.  Cellular immune responses to recombinant antigens in pregnant women chronically infected with Toxoplasma gondii.

Authors:  A F Fatoohi; G J N Cozon; T Greenland; J Ferrandiz; J Bienvenu; S Picot; F Peyron
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

3.  B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii.

Authors:  P C Sayles; G W Gibson; L L Johnson
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

4.  Estimation of the avidity of immunoglobulin G for routine diagnosis of chronic Toxoplasma gondii infection in pregnant women.

Authors:  G J Cozon; J Ferrandiz; H Nebhi; M Wallon; F Peyron
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-01       Impact factor: 3.267

5.  Limited value of assays using detection of immunoglobulin G antibodies to the two recombinant dense granule antigens, GRA1 and GRA6 Nt of Toxoplasma gondii, for distinguishing between acute and chronic infections in pregnant women.

Authors:  Josette Ferrandiz; Corinne Mercier; Martine Wallon; Stéphane Picot; Marie-France Cesbron-Delauw; François Peyron
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

Review 6.  Applications of flow cytometry to clinical microbiology.

Authors:  A Alvarez-Barrientos; J Arroyo; R Cantón; C Nombela; M Sánchez-Pérez
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

7.  Cellular immunity to Toxoplasma gondii in congenitally infected newborns and immunocompetent infected hosts.

Authors:  A F Fatoohi; G J N Cozon; M Wallon; S Kahi; F Gay-Andrieu; T Greenland; F Peyron
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-04       Impact factor: 3.267

8.  Heterogeneity in cellular and humoral immune responses against Toxoplasma gondii antigen in humans.

Authors:  A F Fatoohi; G J N Cozon; P Gonzalo; M Mayencon; T Greenland; S Picot; F Peyron
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

9.  Systemic T cell response to Toxoplasma gondii antigen in patients with ocular toxoplasmosis.

Authors:  Fatih Fatoohi; Grégoire Jacques Noël Cozon; Martine Wallon; Laurent Kodjikian; François Peyron
Journal:  Jpn J Ophthalmol       Date:  2006 Mar-Apr       Impact factor: 2.211

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.